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Stem cell plasticity: time for a reappraisal? 
In classical developmental biology,pluripotency and plasticity are consid-ered properties of early embryonic stem
cells (ES), while adult stem cells (SC) are
traditionally thought to be restricted in
their differentiation potential to the proge-
ny of the tissue in which they reside. In
higher vertebrates, most adult tissues and
organs contain SC capable of self-renewal,
proliferation, and differentiation into
mature, functional progeny. These SC are
more abundant in tissues with a high
renewal rate, such as blood, epithelia, or
the vasculature, and less abundant in tis-
sues or organs with little renewal capacity,
such as myocardial muscle or the central
nervous system (CNS). In the last few
years, a number of reports from many dif-
ferent groups have claimed a remarkable
plasticity in the differentiation potential of
SC derived from adult tissues such as the
bone marrow (BM), the skeletal muscula-
ture, or the CNS. In all cases, differentia-
tion of a SC into a non-canonical progeny
(transdifferentiation), e.g., muscle or liver
from BM SC, was a rare phenomenon,
almost invariably associated with severe
damage in the target tissue1,2 and often with
a specific selective pressure for the trans-
differentiated progeny.3 For instance, one
type of SC – the neurosphere-derived neu-
ral SC - has been reported to turn into a SC
with a completely different genetic pro-
gram – the hematopoietic stem cell (HSC) –
under the strong selective pressure of lethal
myeloablation.4 However, some of these
reports have not been confirmed in subse-
quent investigations.5-7 As an example, the
muscle-derived SC reported to give rise to
HSC upon transplantation8 were subse-
quently shown to be hematopoietic in ori-
gin.9,10 In other cases, cell fusion rather than
transdifferentiation was demonstrated to
be the main mechanism of the observed
plasticity of adult SC.11-13 Neverthless, the
potential plastic properties of adult SC
have an obvious relevance for regenerative
medicine. The possibility of using SC from
easily accessible sources to repair irre-
versibly damaged tissues, such as infarcted
myocardium or cirrhotic liver, or tissues
severely damaged by a genetic diseases,
such as muscular dystrophy, would have a
dramatic therapeutic impact on otherwise
untreatable conditions. 
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In recent years an increasing number of publications have claimed that adult mam-
malian stem cells (SC) may be capable of differentiating across tissue lineage bound-
aries and that this plasticity may represent a novel therapeutic strategy for tissue
regeneration. However, after a first phase of excitement, the issue of somatic SC plas-
ticity remains controversial and the therapeutic perspectives are still elusive. In this
review, we examine the general mechanisms which govern the function of SC, the iden-
tification and functional characterization of adult SC of different tissues and their puta-
tive capacity to transdifferentiate into mature cells of different origin. The potential clin-
ical applications of adult SC for regenerative medicine are also discussed in each
chapter. The method employed for preparing this review was the informal consensus
development. Members of the Working Group on SC met four times and discussed the
single points, previously assigned by the Chairman (S.T.), in order to achieve an agree-
ment on different opinions and approve the final manuscript. All the authors of the
present review have been working in the field of SC and have contributed original
papers to peer-reviewed journals. In addition to the authors’ own work, the present
review examines articles published in journals covered by the Science Citation Index
and Medline.
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Definitions  and general concepts about SC
SC are defined as cells with the unique capacity to
renew themselves and to give rise to specialized cell
types.14 Therefore, SC have the ability to self-replicate
for indefinite periods, perhaps throughout the entire
life of the organism. At variance with the large major-
ity of cells of the body that are committed to a specif-
ic function, SC are uncommitted and remain as such,
until they receive a signal to generate specialized cells.
This class of SC is called pluripotent, since they have
the potential to develop into almost all of the more
than 200 different known cell types. SC with this
unique property come from embryos and fetal tissue.
In 1998, for the first time, investigators isolated this
class of pluripotent SC from early human embryos
and grew them in culture.15 Since then, a large body of
evidence indicates their pluripotent capacity and their
potential to generate replacement cells for a broad
array of tissues and organs.
Adult SC are undifferentiated cells that are found in
differentiated adult tissues. During the past decade,
adult SC have been found in tissues that were not pre-
viously thought to harbor them, such as the CNS.
More recently, it has been reported that adult SC from
one tissue appear to be capable of developing into cell
types that are characteristic of other tissues. Thus, the
new concept of adult SC developmental plasticity has
emerged.16
By definition, the only type of totipotent SC is the fer-
tilized egg, because it can give rise to all the cells and
tissues of the developing embryo. The fertilized egg
divides and differentiates until the development of a
mature organism. A single pluripotent SC has the abil-
ity to give rise to cells originating from all the three
germ layers: mesoderm, endoderm, and ectoderm.
The only known sources of human pluripotent SC are
those isolated and cultured from early human
embryos, ES cells, and those isolated from the primor-
dial germ cells of the gonadal ridge of 5- to 10-week
fetuses or embryonic germ cells (EG cells). It has
recently been described that a subset of adult mes-
enchymal SC (MSC) are also pluripotent.17 Multipotent
SC, such as HSC, can give rise to all blood cells, i.e.
cells of different lineages. Unipotent SC  indicate a cell
population, usually present in adult tissues, capable of
differentiating along only one lineage.
ES cells
ES cells derive from the inner cell mass of the blas-
tocyst-stage of an embryo, prior to implantation in the
uterine wall. ES cells can self-replicate, and give rise to
cells derived from all three germ layers. These cells
proliferate extensively in the embryo, are capable of
differentiating into all adult tissues, and can be isolat-
ed and grown ex vivo, where they continue to replicate
and show the potential to differentiate.15 Much of the
knowledge about ES cells has emerged from applied
reproductive biology, i.e., in vitro fertilization technolo-
gies, and basic research on mouse embryology. ES cell
lines can actually be established from virtually all
mammals. In humans, blastocysts for the establish-
ment of renewable human ES cell lines may actually
be obtained from either supernumerary embryos or
from embryos specifically produced for research pur-
poses (for therapeutic cloning see ref. 18). ES cells can be
propagated – under certain in vitro conditions – almost
indefinitely, while maintaining a normal karyotype
and totipotency, as has recently been shown by cultur-
ing ES cell lines in the presence of leukemia inhibitory
factor (LIF). Cultures of human pluripotent SC have
active telomerase, indicating that they have the abili-
ty to replicate for many generations. 
Current challenges for the therapeutic use of ES cells
are to direct their differentiation into specialized cell
populations, and also to devise strategies to control
their development or proliferation once infused in vivo.
Although a detailed discussion of the properties of ES
cells is not the aim of this review, the main character-
istics defining ES cells are listed in Table 1.
Adult SC
Adult SC (Table 2) have long-term self-renewal
capacity and can give rise to mature cell types with
specialized functions. Typically, SC generate interme-
diate cell types (progenitors and more differentiated
precursors) before they achieve their fully differentiat-
ed state. Progenitors and precursor cells are usually
regarded as committed to differentiate along a specific
cellular pathway. The primary function of SC is to
maintain homeostasis, and, with limitations, to
replace cells dying because of injury or disease. Adult
SC behave very differently depending on their local
environment and tissue origin. HSC are located in the
BM where they differentiate into mature blood cells.
Only 1 in 10,000 to 15,000 BM progenitors is a HSC.14
Conversely, epithelial SC in the small intestine reside
at the bases of crypts, deep invaginations between the
mature, differentiated epithelial cells that line the
lumen of the intestine. These epithelial crypt cells
divide fairly often, but remain part of the stationary
group of cells they generate.19
In order to be classified as an adult SC, the cell
should be capable of self-renewal for the lifetime of
the organism. This criterion, although fundamental to
the nature of a SC, is difficult to prove in vivo. It is
nearly impossible, in an organism as complex as a
human, to design an experiment that will allow the
tracking of candidate SC over the entire lifetime. In
practice, a candidate SC must repopulate the tissue
upon transplantation. An adult SC should also be able
to give rise to fully differentiated cells that have
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mature phenotypes, are fully integrated into the tis-
sue, and are capable of specialized functions that are
appropriate for the tissue.
Adult SC have been identified in many animal mod-
els and human tissues. The list of adult tissues report-
ed to contain SC is growing and includes BM, periph-
eral blood, brain, spinal cord, dental pulp, blood ves-
sels, skeletal muscle, epithelia of the skin and digestive
system, cornea, retina, liver, pancreas, heart, and the
CNS (Table 3 and 4).
The most abundant information about adult human
SC comes from studies on the BM and blood. There
are two major types of SC found in the BM (Table 4):
HSC which generate blood cells, and MSC that sup-
port hematopoiesis and can differentiate into multiple
tissues of the three germinal layers (see below). 
Adult SC regulation
During the process of differentiation, the prolifera-
tive potential of adult SC is progressively lost while
specific differentiation features are acquired.
According to this hierarchical model, the most primi-
tive hematopoietic SC are quiescent, residing in the G0
phase of the cell cycle, and are protected from deple-
tion and exhaustion. Quiescent SC enter the cell cycle
either randomly or under the influence of micro-envi-
ronmental stimuli,20 such as growth factors or
cytokines mainly produced by accessory or differenti-
ated cells of the tissue. 
During their transit through the cell cycle, SC exert
their function. These observations might be explained
by alterations in chromatin structure during cell cycle
progression that could have marked effects on gene
Table 1. Properties of ES cells.
Tissue origin Derived from the inner cell mass/epiblast of the blastocyst.
Long-term Capable of undergoing an unlimited number of symmetrical 
self-renewal divisions without differentiating.
Karyotype Exhibit and maintain a stable, full (diploid), normal
complement of chromosomes.
Pluripotentiality Pluripotent ES cells can give rise to differentiated cell types 
that are derived from all three primary germ layers of the 
embryo (endoderm, mesoderm, and ectoderm).
Capable of integrating into all fetal tissues during
development. Mouse ES cells maintained in culture for long 
periods can still generate any tissue when they are
reintroduced into an embryo to generate a chimeric animal.
Capable of colonizing the germ line and giving rise to egg
or sperm cells.
Clonogenicity A single ES cell can give rise to a colony of genetically
identical cells, or clones, which have the same properties
as the original cell.
ES cells express the transcription factor Oct-4, which then
activates or inhibits a host of target genes and maintains ES 
cells in a proliferative, non-differentiating state.
Cell Fate Can be induced to continue proliferation or to differentiate.
Cell Cycle Lack the G1 checkpoint in the cell cycle. ES cells spend most 
of their time in the S phase of the cell cycle, during which 
they synthesize DNA.
Unlike differentiated somatic cells, ES cells do not require 
any external stimulus to initiate DNA replication.
Table  2. Properties of Adult SC.
Tissue origin Present in many tissues.
Long-term Capable of maintaining homeostasis of the SC
self-renewal compartment for the entire lifetime of the organism.
Karyotype Exhibit and maintain a stable, full (diploid), normal
complement of chromosomes.
Potentiality The large majority of adult stem cells are not pluripotent,
like ES, since they have a limited differentiation capacity.
They can be multi-potent, such as hematopoietic SC or
unipotent such as skin SC. Experimental evidence suggests 
that the only exception are MAPc since these can give rise to 
differentiated cells of all the three types of primary germ
layers of the embryo (endoderm, mesoderm, and ectoderm).
Clonogenicity A single adult SC, in vitro, can only give rise to a colony of
differentiated cells lacking the properties of the original cell
The molecular mechanisms that maintain adult SC cells in a 
proliferative, non-differentiating state are almost completely 
unknown.
Cell Fate Can be induced to differentiate.
Cell Cycle The large majority of adult SC are in a quiescent state.
Adult SC require an external stimulus from the
microenvironment to enter the cycle and initiate DNA
replication (stem cell niche).
Plasticity Adult SC may have the ability to generate specialized cells of 
other tissues. The mechanism is still debated (cell fusion ? 
transdifferentiation ?)
Table 3. Adult SC types and their developmental plasticity.
Tissue of Cell Species Tissue Tissue formed
origin type damage In vitro In vivo
Muscle Satellite cells − − − −
Skin Epithelial SC − − − −
CNS Neural SC Mice TBI − BM, Muscle
Liver Hepatocytes, oval cells° Rat STZ* Pancreas Pancreas
Kidney Renal SC − − − −
MSC Human − BM, Liver −
Pancreas Pancreatic SC Rat − Liver −
Heart Cardiac SC Mice TBI − Endothelium
Example of developmental plasticity of SC types discussed in this review. 
The frequency of transdifferentiation to tissues different from that of origin,
in vivo is either minimal or not present. Endothelial SC are included in Table 4
within BM-derived SC. For appropriate references see the text;
*STZ: streptozotocin; °Only oval cells showed the capacity to generate pancreatic
endocrine hormone-producing cells, in vitro and in vivo.
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expression and therefore on cell fate. A decreased con-
centration of growth factor when stem or progenitor
cells are actively proliferating can lead to a cell cycle
arrest in G1 and to the possibility that these arrested
cells activate different genetic programs such as differ-
entiation, apoptosis or reverse cell cycle progression
toward G0. Many data exist to support such a hierar-
chical model: (i) marrow cells have been separated
based on their repopulating potential and progenitors
have been characterized as exclusively committed to
the production of restricted progeny; (ii) expansion of
different progenitor types in cytokine-stimulated in
vitro culture with loss of long-term engraftment capac-
ity demonstrates the existence of a progenitor hierar-
chy, at least of the more differentiated progenitor cells.
However, this hierarchical model has been chal-
lenged.21 In fact, rather than hierarchical transition
from SC to progenitor cells, it appears that a fluctuat-
ing continuum exists, in which the phenotype of SC
shifts from one state to another and back depending
on the cells’ kinetic state. These phenotypic shifts are
based on chromatin remodeling associated with cell
cycle transit and particularly with the G1 phase of the
cycle, which reversibly alters the surface phenotype of
SC determining their response to environmental stim-
uli. According to this model of competence and pro-
gression, studied in fibroblasts, quiescent SC may pro-
liferate and maintain their renewal capacity and then
return to G0 due to a drastic drop in growth factor con-
centration.22 This mechanism can explain the mainte-
nance of the SC pool with kinetically quiescent cells.
On the other hand, it is possible that cell cycle transit,
particularly in the G1 phase, in which gene transcrip-
tion is much more efficient, is associated with a con-
Table 4. BM-derived SC types and their developmental plasticity.
Cell type Species Tissue damage Tissue formed Frequency (%)
In vitro In vivo
MAPc Mice, Rat, Human None or TBI Multiple tissues Multiple tissues 0-12.5
of the 3 germinal layers of the 3 germinal layers
MSC* Mice, Rat, Human None or TBI Chondroblasts Chondroblasts
Skeletal muscle Skeletal muscle
Osteoblasts Osteoblasts
Candroblasts Candioblasts
Adipocytes Adipocytes
Neural Cells Neural Cells
Unfractionated Mice TBI Pancreas 1.7-3
Unfractionated Rat CCl4 Liver 0.14
Unfractionated Human (BM,PB) TBI Liver 
Skin 5-7
Intestinal 2-6
Epithelium 4-6
HSC Unfractionated° Human, Mice TBI CNS
Unfractionated (Purified) Mice TBI ± genetic deficiency Skeletal muscle From rare
(mdx mice) to <10
Unfractionated° Mice, Dog Ischemia ± TBI Cardiac muscle ± vasculature 2-25
Unfractionated Mice, Human TBI Liver 2.2
c-Kit Mice STZ Pancreas 14
Sca + Mice Ischemia Kidney 2-21
KTSL° Mice TBI + FAH Liver rare
CD34 + Human ?Mice TBI ± CCl4 Liver −
CD34 + Mice Ischemia Vasculature 20-25
Homed SC Mice TBI Multiple epithelial tissues 0.19-20
Monocyte precursor° Mice TBI Skeletal muscle From rare to < 10 
SP° Mice, Human TBI ± Ischemia Liver, cardiac, muscle, 0.02-4
endothelial cells
SP° Mice TBI ± genetic deficiency Skeletal muscle 1-10
(mdx mice)
c-kit+ Lin -° Mice Ischemia Cardiac muscle 54
and vasculature
TBI: Total-body irradiation; KTSL, c-Kit+,Thy-1LOW, sca-1+ and lineage markers -; STZ, streptozotocin; “HOMED HSC”, single HSC that homed to the BM after
transplantation and not divided progenitor cells; MSC: mesenchymal SC; SP: side population; FAH: fumarylacetoacetate; MAPc: multipotent adult progenitor cells.
*MSC with capacity to differentiate to tissues different from that of origin were also found in the kidney, adipose tissue, dental pulp, and CNS. °Cell fusion mechanism
was demonstrated. For appropriate references and details see the text.
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tinuously changing SC phenotype depending on dif-
ferent genetic programs activated by micronviron-
mental stimuli that differ in the different areas of the
tissue and therefore lead to SC commitment, differen-
tiation, apoptosis or to developmental plasticity. In
fact, one can speculate that such flexibility might also
explain the recently described transdifferentiation of
marrow SC to non-hematopoietic cells in different tis-
sues (Figure 1). In conclusion, according to this model,
the kinetic status of SC is very important since only
proliferating SC can move backward to the G0 phase
of the cell cycle, undergo differentiation, apoptosis or
transdifferentiation.
Identification of SC in adult tissues and
models of differentiation across lineage
boundaries (developmental plasticity)
Pancreatic SC and models of transdifferentiation into
pancreatic tissue
Several experimental models have demonstrated
that both the endocrine23,24 and the non-endocrine25,26
compartments of the pancreas contain multipotent
progenitors capable of differentiating into pancreatic
islet-like structures. Moreover, recent data demon-
strate that adult pancreatic insulin-producing cells are
capable of replicating themselves.27 However, the pres-
ence of additional sources of pancreatic precursor cells
has recently been reported. Murine and human
pluripotent ES cells have been shown to differentiate
into insulin-producing cells with the ability to cure
diabetic mice.28 Furthermore, adult hepatic oval SC
have demonstrated the capacity to generate function-
al endocrine pancreas under culture conditions similar
to those used to differentiate pancreatic SC into
insulin-secreting‚ cells.29 On the other hand, pancreat-
ic SC possess the ability to differentiate into liver
cells.30 These findings, coupled with the notion that
both the liver and the ventral pancreas seem to devel-
op from the same cell population within the embryon-
ic endoderm, strongly suggest that liver and pancreas
share common SC whose differentiation is deter-
mined by their location, by local growth factors, glu-
corticoids or by the induction of the transcription fac-
tor C/EBPβ‚ which is the the key factor dictating
hepatic cell differentiation from terminally differenti-
ated pancreatic elements.30 Recently, two different
groups have reported that BM-derived SC can differ-
entiate into pancreatic islet cells.31,32 In the first study,31
murine male green fluorescent protein positive (GFP+)
unselected BM cells were transplanted into irradiated
female recipients. After 4 to 6 weeks from transplant,
GFP+, Y-chromosome+ and insulin+ cells were detected
Figure 1. Hierarchical and kinetic models: transdifferentiation of marrow SC to non-hematopoietic cells in different tissues.
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in the islets. Molecular analysis showed the expres-
sion of pancreas islet markers such as insulin I, II,
GLUT-2, IPF-I, HNF1a, HNF-1b and PAX6 in 1.7-3%
of analyzed cells. Functionally, the BM-derived pan-
creatic cells showed a physiological behavior typical
of β cells by secreting insulin upon stimulation with
glucose or the glucagon-like peptide exendin. In the
same paper, the authors ruled out that cell fusion
between BM and pancreatic cells had occurred. To test
this issue, female stop-lox GFP mice, in which GFP is
expressed after recombination by cre recombinase,
were transplanted with male BM cells expressing cre
recombinase. The fact that Y+, GFP-negative pancreat-
ic cells were found suggests that no fusion had
occurred.31,32 Hess et al.32 transplanted c-kit+ BM cells
into recipient mice with streptozocin-induced pancre-
atic damage. Using this model of chemical injury, the
authors demonstrated the capacity of partially puri-
fied BM SC to differentiate, at low frequency, into
fully functional ductal and islet structures. These stud-
ies underline the concept that different methods
should be combined to obtain reliable analysis of
insulin-expression by pancreatic cells. A recent report33
demonstrates that ES cells can be positively stained
with antibodies to insulin taken up from the culture
medium. 
Kidney SC and evidence that BM SC contribute to
repair injured renal tissue
Epithelial cells within the renal tubules are believed
to represent the kidney SC population as they dedif-
ferentiate to a more mesenchymal phenotype and
then proliferate in response to acute tubular necrosis
to repair the injured tissue.34 Kidney progenitor cells,
capable of undergoing complete nephrogenesis and
potentially suitable for transplantation, can also be
isolated from human embryos of 7 to 8 weeks.35
Recent data indicate that human BM cells might con-
tribute to the generation of both epithelial36,37 and non-
epithelial38-40 cell types in the kidney. The presence of
Y-chromosome+ epithelial renal cells in males who had
received a kidney transplant from a female donor was
shown, thus suggesting an alternative source of kid-
ney SC. Kale et al. have used a model of ischemic renal
damage to demonstrate the ability of murine BM-
derived SC (Lin-Sca+) to mobilize in response to
ischemic injury and to differentiate into renal tubular
cells within 48 hours in order to contribute to tissue
repair.41 After surgical clamping of the renal artery fol-
lowed by reperfusion, up to 20.9% of outer medulla
renal tubules contained BM-derived cells which con-
tributed to the significant reduction of blood urea
nitrogen as compared to that in mice which did not
receive BM cells. Interestingly, Lin+ cells (i.e. cells
already committed to the lympho-hemopoietic line-
age) did not show differentiation into epithelial cells. 
BM to liver
In contrast to other regenerating tissues, liver regen-
eration after tissue damage is not dependent on only
one class of progenitor/stem cells.42 At least two resi-
dent cell populations have been shown to act as puta-
tive SC. Whereas moderate cell loss is restored by
mature hepatocyte self-renewal, more severe liver
injury induces the activation of a facultative SC com-
partment located within the smallest branches of the
intrahepatic biliary tree, the so-called oval cells which
give origin to hepatocytes and the bile duct epitheli-
um. Of note, liver oval SC express the antigens CD34
and c-Kit, which are strongly associated with the
hematopoietic stem/progenitor cell phenotype.43 At
the time of writing, a few patients have been succes-
fully transplanted with allogeneic hepatocytes to cor-
rect inherited liver-based metabolic disorders.44,45
These preliminary results suggest that transplantation
of less than 5% of total hepatic mass induces at least
a partial correction of the metabolic abnormalities. 
Recently, a third source of liver-repopulating cells
has proven to be the BM. Petersen et al.46 transplanted
syngeneic male BM cells into lethally irradiated female
recipient rats that had been treated with 2-acety-
laminofluorene, to inhibit hepatocyte proliferation,
and then received hepatic injury by carbon tetrachlo-
ride (CCI4) to induce oval cell activation. Donor-
derived, Y-chromosome+ oval cells and mature hepa-
tocytes were found 9 and 13 days after liver damage,
respectively. Additional evidence of a BM-derived
hepatic SC came from Theise et al.47 who also used a
gender mismatch BM transplantation strategy to track
donor-derived SC in the liver of lethally irradiated
mice. This study provided at least two important find-
ings: (i) BM may contribute to normal renewal of liver
tissue in the absence of obvious damage; (ii) regenera-
tion of hepatic tissue could be accomplished by HSC
since 200 CD34+Lin– cells produced the same degree of
engraftment (1-2% at 6 months) as did 20,000 unsep-
arated BM cells. Two further studies48,49 demonstrated
that, also in humans, hepatocytes can derive from BM.
Both groups examined the livers of female patients
who had received a BM transplant from a male donor
and female livers transplanted into male recipients
which had to be removed for recurrent disease. Using
in situ hybridization for Y-chromosome analysis, 4 to
43% hepatocytes and 4 to 38% cholangiocytes were
found to be of extrahepatic origin.49 Taken together,
these studies provided the proof of principle that BM
contributes to liver regeneration. Further investiga-
tions were then addressed to important issues such as
the functional capacity of marrow-derived hepatic
cells, the BM cell type involved in liver tissue differen-
tiation, the molecular mechanisms regulating the
recruitment of marrow cells into liver and finally some
studies challenged the concept of SC plasticity itself.
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Lagasse et al.,3 used BM transplantation in female
recipients deficient in the enzyme fumarylacetoac-
etate hydrolase (FAH-/-), an animal model of fatal
hereditary tyrosinemia type I. FAH-deficient mice die
after birth unless rescued with NTBC, a compound
that prevents the accumulation of toxic metabolites in
the tyrosine catabolic pathway. Liver function was
restored by transplantation of 106 unfractionated wild-
type (FAH+/+) BM cells or by 50 highly purified
hematopoietic c-Kit+Thy+–Lin– Sca-1+ SC. Interestingly,
only HSC, and not committed precursors, showed the
capacity to differentiate into hepatocytes and to res-
cue an otherwise lethal metabolic disease. More
recently, Wang et al.50 transplanted purified human
hematopoietic CD34+ or CD34+ CD38–CD7– SC into
non-obese diabetic, severe combined immunodefi-
ciency (NOD/SCID) and NOD/SCID β2microglobulin
(β2M)-null mice. One month after the transplant, CCl4
was given to mice to induce severe liver damage and
hepatocyte proliferation. Four weeks later, the livers
were harvested and the expression of mRNA for
human albumin and CK19, a marker of bile duct cells,
was found. Human albumin was also found in the
serum of mice and the results were improved by the
administration of hepatocyte growth factor (HGF).50
Taken together, these studies provide strong evidence
that both murine and human HSC can generate fully
functional hepatic tissue. Furthermore, it was demon-
strated that even a single CD34+Lin–Sca+ cell can give
rise (with variable efficiency) to epithelial cells in dif-
ferent organs of recipient animals, including <1% of
biliary cells.1 A non-hematopoietic population of mes-
enchymal multipotent adult progenitor cells (MAPc),
which can differentiate into multiple lineages, has
been isolated from the BM.17 Murine and human
MAPc can differentiate into functional hepatic tissue
in vitro producing albumin and urea and capable of
storing glycogen.51 Thus, different cellular types from
the BM or the peripheral blood52 of hematopoiet-
ic1,3,46,53,54 and non-hematopoietic origin17,51 share the
capacity to generate hepatocytes. This finding sup-
ports the concept that plasticity may not be restricted
to a unique SC population but, rather, may be a gen-
eral property of marrow cells that redirect their tran-
scriptional program under appropriate stimuli. In this
view, the so-called BM side population (SP), which is
characterized by its capacity to efflux the Hoechst
33342 dye, is capable of engrafting into the damaged
liver and to contributing to liver repair.55 Interestingly,
SP CD34low/negative marrow SC share many functional
properties, including the potential for differentiation
into tissues other than the original one, with SP SC
found in skeletal muscle and liver.55 
Very recently, the mechanisms leading to the hom-
ing of HSC to the liver have been investigated.56 The
chemokine stromal cell-derived factor-1 (SDF-1),
which is a pivotal molecule for SC migration and BM
homing, was found to be expressed after irradiation of
liver bile duct epithelium of NOD/SCID mice; further-
more, its expression was upregulated by hepatic CCl4-
mediated damage. Human CD34+CD38– HSC trans-
planted into immunocompromised mice migrated to
the liver whereas the inhibition of SDF-1 receptor
CXCR4 abolished their engraftment. HGF and stem
cell factor, which are secreted after liver injury,
increased the expression of CXCR4 and SDF-1 thus
augmenting the recruitment of marrow cells to the
liver.56 This study underlines the potential of CD34+
cells to migrate in response to stress signals in order to
repair non-hematopoietic tissue. However, when the
kinetics of liver repopulation after BM transplantation
was studied, Wang et al.57 found that the appearance of
BM-derived hepatocytes was quite slow and ineffi-
cient with the first cells being detectable after 2
months with a frequency of only 1/150,000 which is
below any therapeutic threshold.  Finally, it should be
mentioned that two recent studies11,12 have challenged
the concept of SC transdifferentiation potential by
showing that cell fusion is the main mechanism by
which HSC acquire the function of mature hepato-
cytes. Therefore, investigators should test, when pos-
sible, whether cell fusion is responsible for the repro-
gramming of the gene expression pattern and function
of adult SC. In this view, Harris et al.58 using the
Cre/lox system in a transplant model and Jang YY et
al.59 in vitro and in vivo, have shown that HSC can con-
vert into liver,58,59 lung, and skin cells58 without fusion.
Thus, it may be possible that cell fusion occurs on the
basis of the type of damage. Whereas FAH mice are
rescued by a cell fusion mechanism, true differentia-
tion of HSC into liver cells takes place after irradia-
tion.58
Muscle SC
Adult skeletal muscle fibers harbor mononucleated
quiescent precursor cells called satellite cells. These
cells are located along the muscle fibers, between the
sarcolemma and the basement membrane, and con-
tribute myonuclei to growing fibers during postnatal
growth and to regenerating fibers after tissue injury.60
Satellite cells are also capable of self-renewal, but their
number, which is highest in postnatal muscle, declines
with age. During adult life, satellite cells remain quies-
cent and once they become activated by injury they
start to express myogenic regulatory factors, as do
muscle precursors during skeletal muscle develop-
ment. Until recently, the identification and the isola-
tion of satellite cells was quite difficult, since it was
based on electron microscopy detection. The discov-
ery of proteins differently expressed by satellite cells
and myofibers has contributed to their isolation and
functional characterization.61
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The myogenic potential of adult HSC
The first demonstration of non-canonical differenti-
ation of adult SC came from studies showing that BM-
derived cells participate in the repair of damaged mus-
cle upon transplantation into irradiated recipient
mice.62 Subsequent reports have shown that BM-
derived cells63 or SC-containing fractions64 are recruit-
ed to myogenic differentiation and restore dystrophin
gene expression in a murine model of dystrophin-defi-
cient (Duchenne’s) muscular dystrophy. The origin of
the BM-derived myogenic cells and their physiological
role, if any, in the homeostasis of muscle tissue, are
still uncertain. The existence of a circulating myogenic
progenitor cell derived from the BM is not predicted
on the basis of classic embryology, which ascribes the
origin of all skeletal myogenic cells to the somites.
One possibility is that BM-derived myogenic cells
originate from multipotent MSC located in the BM
stroma. However, recruitment of MSC or MAPc to
myogenesis has never been observed in vivo. On the
other hand, transplantation of purified hematopoietic
cell fractions indicate that cells endowed with myo-
genic potential in vivo derive from the hematopoietic
rather than from the stromal fraction of the BM.64-66
However, it remains to be defined whether SC direct-
ly or their differentiated progeny are recruited to the
muscle and induced to myogenic differentiation, and
whether HSC transdifferentiate into a muscle-specific
stem/progenitor cell (e.g. a satellite cell), or directly
into a terminally differentiated progeny (i.e. the mus-
cle fiber). 
Very recent data, based on the use of hybrid LysM-
Cre/ ROSAflox/STOP transgenic mice, suggested a role for
the myeloid lineage in the generation of newly formed
myotubules.67 However, the rigor of this finding is
challenged by the demonstration that the LysM pro-
moter is indeed active in fully pluripotent HSC.68 A
better definition of the cells capable of changing fate
in response to these signals, as well as a better knowl-
edge of the signals themselves, is therefore needed in
order to understand the blood-to-muscle transition
fully. Expansion of transplantable hematopoietic cells
and active recruitment to myogenic differentiation
are in fact critical factors for a possible use in cell/gene
therapy of muscular dystrophy.
SC transplantation for muscular dystrophy: a
therapeutic perspective?
Duchenne’s muscular dystrophy (DMD) is due to
the total or partial deficiency of dystrophin, a compo-
nent of the multi-protein complex linking the
cytoskeleton of the muscle fiber to the extracellular
matrix. In the absence of dystrophin, the complex is
functionally impaired, and the mechanical stress asso-
ciated with contraction progressively leads to degen-
eration of skeletal muscle fibers, muscle wasting, pro-
gressive impairment of movements, and eventually
paralysis and death. The current therapeutic
approaches to DMD involve pharmacological control
of inflammation, which achieves beneficial effects but
has no impact on the life expectancy of the patients.
Gene therapy of DMD is based on the concept of pro-
viding a copy of a normal dystrophin cDNA to muscle
fibers or satellite cells, in vivo or ex vivo. The discovery
that transplantable, BM-derived cells may give rise to
muscle tissue under certain experimental circum-
stances has obviously raised much hope for a new
form of cell-based therapy of DMD.
From the clinical point of view, however, the studies
on mdx mice have been disappointing. They showed
that after BM transplantation less than 0.5% of the
muscle fibers of the recipient mice are reconstituted
by a donor cell source, with no practical impact on the
murine pathology. The implication of these findings is
that either the efficiency of the myogenic conversion
is too low to be practically useful, or that the mdx
background does not provide enough differentiation
stimuli, or selective advantage, to hematopoietic cells
to trigger their expansion and the replacement of the
resident muscle cells. 
More recently, a possible alternative to BM-derived
primary cells has been developed in the murine sys-
tem. This is represented by blood-vessel associated,
multipotent progenitor cells – the so-called mesoan-
gioblasts – which have the capability to differentiate
into muscle tissue in vivo with a relatively high effi-
ciency. Mesoangioblasts are derived in culture by
clonal expansion of embryonic or fetal aorta-derived
mononuclear cells, and have the remarkable property
of homing and differentiating into muscle fibers when
delivered to a muscle through the arterial circulation.
Intra-arterial delivery of genetically-modified mesoan-
gioblasts led to repopulation and massive replacement
of sarcoglycan-deficient fibers in a murine model of
limb-girdle muscular dystrophy.69 This study indicates
that mesoangioblasts that have been expanded in vitro
from an easily accessible source may be genetically
modified and used as a combined gene/cell therapy to
treat muscular dystrophy.
The role of endothelial stem/progenitor cells (EPC) 
in health and disease
Until recently, it was thought that vasculogenesis
(EPC-derived generation of new vessels) is restricted
to the period of embryonic development, whereas in
the adult only angiogenesis (sprouting from mature
endothelial cells) contributes to the generation of new
blood vessels.70 During antenatal life, EPC and HSC
are thought to derive from a common progenitor, the
hemangioblast.71 In adult life, there is increasing evi-
dence that HSC provide functional hemangioblast
activity (see below).
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EPC may persist in the marrow and circulate in the
blood during adult life.72 In fact, recent preclinical and
clinical studies have indicated that EPC can restore tis-
sue vascularization and that the growth of some neo-
plastic diseases may depend on EPC-induced vasculo-
genesis rather than on angiogenesis.73
The presence of marrow-derived EPC able to partic-
ipate in vasculogenesis was first demonstrated in 1998
by Shi et al.74 in a canine bone marrow transplantation
model: when a Dacron graft was implanted 6-8
months after transplantation, only donor endothelial
cells colonized the vascular prosthesis. In a transgenic
mouse model expressing a marker gene under the
transcriptional regulation of an endothelial-specific
promoter (Flk-1 or Tie-2), marrow-derived EPC were
found to generate new vessels in the endometrium
after ovulation, in implanted colon tumors, in cuta-
neous wounds and in neovascularization foci at the
border of myocardial infarcts generated by coronary
ligation.75 Circulating EPC have been detected in the
blood after vascular injuries, vascular trauma induced
by burn injury, or in neoplastic patients.73 In fact, vas-
cular trauma and organ regeneration may result in the
release of EPC-mobilizing chemokines and/or VEGF-
A. This latter molecule, is currently considered the sin-
gle most potent growth factor promoting ESC mobi-
lization in a complex mechanism mediated through
activation of metalloproteinases (MMP) and adhesion
molecules. 
EPC can be distingushed from the larger population
of circulating mature endothelial cells (CEC) by the
expression of CD133 antigen. In addition to the mar-
row, it seems possible that the parenchyma of the sys-
temic vasculature or certain organs may host embed-
ded EPC. For example, EPC isolated from the skeletal
muscle accordingly to the side population phenotype
can differentiate into mature endothelial cells.76
The role of EPC in revascularization 
Retinal and brain revascularization
Diabetes and age-related prematurity and macular
degeneration are associated with abnormal compensa-
tory choroidal and retinal neovascularization, which,
in turn, can lead to proliferative retinopathy. SC have
been shown to contribute to retinal neovessel forma-
tion. In murine studies, a single GFP-expressing Sca1+c-
Kit+Lin– cell injected into lethally irradiated mice result-
ed, after ischemia-induced laser occlusion, in the incor-
poration of donor-derived GFP+ endothelial cells into
retinal neovessels.77 In another study, Lin– progenitors
were intravitreally injected into neonatal and adult
mice with photocoagulated retinas. Surprisingly, Lin-
cells were localized into the astrocytes and formed reti-
nal vessels. This study indicated that astrocytes may
promote the differentiation and incorporation of mar-
row–derived EPC into functional vessels.78
Neovascularization near the ischemic boundary
zone is frequently observed after a cerebral infarction.
Transplantation of male-derived donor marrow cells
into female mice, who were later subjected to middle
cerebral artery occlusion, has been associated with a
predominance of donor-derived cells in the vascula-
ture repair site 3 days after occlusion.79
Graft revascularization
Autologous vascular grafts or a decellularized matrix
are used to replace altered coronary arteries.
Thrombus generation on the matrix-blood contact
surface is one of the most frequent complications. EPC
can generate non-thrombogenic mature vascular cells
to coat decellularized or biodegradable surfaces. After
the pioneering canine study by Shi et al.,74 marrow
cells have been embedded into synthetic prostheses
before grafting into the aortas of dogs, resulting in
generation of a non-thrombogenic endothelialized
surface. Autologous ovine EPC were also seeded on
decellularized vessels and grafted into carotid arteries
to generate non-thrombogenic functional vessels that
remained patent with no occlusions for 120 days, in
contrast to the endothelial-free vascular grafts that
formed thrombi.80 Thus, graft precoating with EPC-
derived mature endothelium may facilitate in vivo
remodeling.
Limb ischemia
Autologous marrow cells injected into ischemic gas-
trocnemius muscle restored limb function in preclini-
cal studies of peripheral arterial disease and in prelim-
inary clinical observations.81 Given the use of crude
marrow cell suspensions, it remains to be determined
whether these results were due, at least in part, to
hematopoietic cells. It should be noted, however, that
revascularization of ischemic limbs depends on the
balanced formation of blood and lymphatic vessels,
because lymphatic dysfunction results in edema and
non-healing ulcers. Overexpression of VEGF-C has
accelerated functional recovery of ischemic limbs by
enhancing lymphangiogenesis and angiogenesis and
decreasing edema formation.82
Myocardial regeneration and revascularization
It has been reported that marrow cells may differen-
tiate into myogenic and vascular cells in a process
defined as angiomyogenesis. In murine studies on
infarcted animals, mobilized VEGFR2+, CD117+ cells
homed to the infarcted tissue and contributed to
neoangiogenesis.83 In other studies, marrow–derived
CD117+ or side population cells injected into the
infarction site differentiated into myocardial cells and
mature endothelium.84-86 Furthermore, injection of
human CD34+ or autologous CD31+ marrow cells into
rats increased vessel density during ameroid-induced
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blood vessel constriction and ischemia.87,88 In a very
interesting recent study, the injection of marrow cells
transduced with the prosurvival gene Akt1 (encoding
the Akt protein) into ischemic rat myocardium inhibit-
ed cardiac remodeling by reducing intramyocardial
inflammation, collagen deposition and cardiac
myocyte hypertrophy, and regenerated most of the
lost myocardial volume, and completely normalized
systolic and diastolic cardiac function.89 Taken togeth-
er, these preclinical studies suggest that direct intro-
duction into a permissive infarcted or ischemic
myocardium may allow progenitor cell incorporation,
neoangiogenesis and improvement of cardiac function.
In pioneering human clinical studies, crude autologous
marrow cell suspensions have been delivered by arte-
rial catheters into coronary arteries to repair infarcted
and ischemic tissues by transendocardial injections or
guided electrochemical mapping.90-92 In other settings,
the clinical efficacy of ex vivo expanded peripheral
blood mononuclear cells was compared to that of mar-
row–derived EPC in restoring revascularization after
acute myocardial infarction.93 Interestingly, some
investigators have also studied the injection of puri-
fied, marrow-derived CD133+ cells into the infarcted or
ischemic areas, with or without concomitant coronary
artery bypass grafting. Blood flow and ventricular
function improvements observed in these patients
indicate that such procedures are feasible, safe and,
possibly, clinically effective.94 A first randomized clini-
cal trial has demonstrated that, in patients affected by
myocardial infarction, intracoronary-injected autolo-
gous marrow cells can improve the ejection fraction
evaluated six months after a percutaneous coronary
intervention.95 However, though neoangiogenesis from
BM-derived SC seems to be well established, the
capacity of HSC to transdifferentiate into cardiomy-
ocytes is still debated.96,97 In addition, recent experi-
mental and clinical data98,99 have shown restenosis of
coronary arteries following BM SC therapy, thus sug-
gesting that the route of administration of BM cells
may be important for cellular therapy.
Two recent reports have proposed the existence of
adult heart-derived cardiac progenitor cells. Oh et al.100
identified a murine population of cardiac stem cell can-
didates expressing Sca-1. Initially, these cells expressed
neither cardiac structural genes nor Nkx2.5 but they
differentiated in vitro in response to 5'-azacytidine, in
part depending on Bmpr1a, a receptor for bone mor-
phogenetic proteins. Given intravenously after
ischemia, these cells engrafted in injured myocardium.
By using a Cre/Lox donor/recipient pair, differentia-
tion was shown to occur almost equally, with and
without fusion to host cells. Beltrami et al.,101 have
reported the existence of Lin– c-kit+ cells with the
properties of cardiac SC. These cells are self-renewing,
clonogenic, and able to generate myocytes, smooth
muscle, and endothelial cells. When injected into an
ischemic heart, these cells (or their clonal progeny)
were able to reconstitute well-differentiated myo-
cardium and new vessels.
Neural SC and their use as a therapeutic tool
in neurological disorders
Neural SC (NSC) are considered a heterogeneous
population of mitotically-active, self-renewing, multi-
potent cells of both the developing and the adult nerv-
ous system showing complex patterns of gene expres-
sion that vary in space and time. Early in the 1960s,
neural cells behaving as SC entities were isolated from
the embryonic mammalian central as well as peripher-
al nervous system.102,103 Since then, SC have been isolat-
ed from virtually the entire adult CNS and regions such
as the subventricular zone (SVZ) of the lateral ventri-
cles, the dentate gyrus and the cerebral cortex have
been shown to contain stem-like cellular elements.104
During development, the frequency of NSC decreases
over time, while the activation of cellular programs of
differentiation into lineage (neuronal or glial)-restricted
precursors increases.105 In the adult CNS, stem-like cells
– although showing modest proliferation characteris-
tics – are capable of driving neurogenesis in specialized
regions of the brain (i.e. the olfactory bulb, the hip-
pocampus, the SVZ, the central canal of the spinal
cord), which behave as highly specialized tissue nich-
es. On the other hand, cycling progenitor cells of
apparent glial lineage, distributed throughout the
whole brain parenchyma, drive adult gliogenesis.
Independently of the accepted terminology – SC,
precursors or progenitors – the origin of this discrete
population of undifferentiated neural cells is still debat-
ed. So far, two principal theories have been postulated.
One theory claims that the true NSC of the adult SVZ
differentiate from ependymal cells expressing the
intermediate filament protein nestin,106 while the other
theory identifies NSC as slowly dividing astrocyte-like
- type B – subependymal cells expressing glial fibrillary
acidic protein (GFAP) and nestin.107 These multipotent,
type B NSC – which reside within the SVZ – are
believed to generate in vivo at least three different pop-
ulations of lineage-committed transit-amplifying pro-
genitors [type C, type D cells and white matter progen-
itor cells (WMPC)] of both neuronal and glial pheno-
type. 
Endogenous NSC for brain repair
There is compelling evidence that NSC may concur
in brain repair during adult life. Notably, it has been
recently shown that endogenous NSC may sustain
neurogenesis and gliogenesis in response to several
different injuries such as those occurring during
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inflammatory, ischemic, or traumatic events.108,109
These pathogenic events might trigger a cascade of
cellular and molecular signals – possibly via the release
of soluble mediators (cytokines, chemokines, metallo-
proteases, adhesion molecules, etc.) that are capable of
supporting neurogenesis and gliogenesis which, in
turn, drive brain repair. In chronic experimental
autoimmune encephalomyelitis (EAE), the animal
model for multiple sclerosis (MS), mitotically active
progenitor cells, residing either in the SVZ of the brain
or in the subependymal layer of the central canal of
the spinal cord, subvert their physiological destiny –
migration along the RMS to the olfactory bulb or to
the lateral columns of the spinal cord – and migrate
into areas of demyelination where they differentiate
into glial cells.108 In experimental models of spinal cord
injury (SCI) or ischemic stroke, neurogenesis of
endogenous NSC –residing close to the traumatized or
ischemic regions and surviving the injury –occurs
within one week after the pathogenic event. In fact,
nestin-reactive proliferating progenitor cells have been
found at the border of ischemic and traumatized areas
while supporting post-injury neurogenesis within a
zone comprised between the damaged tissue and the
surrounding intact cerebral parenchyma.109
The accumulating evidence indicating that endoge-
nous neurogenesis and gliogenesis occur as part of an
intrinsic brain self-repair process during adulthood sup-
ports the ensuing idea of developing alternative thera-
peutic strategies for brain disorders based on the use
of NSC transplants.
NSC transplantation in CNS disorders
In CNS disorders characterized by neuronal or glial
loss – e.g. stroke, Parkinson’s disease, MS, SCI – cell-
based replacement therapies may represent a promis-
ing alternative therapeutic approach. However, there
are some preliminary questions that need to be solved
before envisaging any potential human applications of
such therapies: (i) the ideal cell source for transplanta-
tion; (ii) the route of cell administration; (iii) the differ-
entiation and persistence of NSC in the targeted tis-
sue. Furthermore, functional and long-lasting integra-
tion of transplanted cells into the host tissue has to be
achieved.
The source of cells
The gold standard cell for replacement therapies
must, in essence, be plastic. SC meet this criterion
since they are intrinsically able to adapt their specifi-
cation fate to different environmental needs. Both ES
cells and adult NSC could be ideal cell sources for cell
replacement-based therapies in CNS disorders.
Embryonic neural cells, although representing a prom-
ising source of NSC, have not been consistently used
so far for transplantation purposes.
ES cells
ES cells can be induced to differentiate in vitro into
almost all cell types of the body including neural cells;
these can be obtained by growing the ES cells in the
presence of trophic factors such as epidermal growth
factor (EGF), platelet-derived growth factor (PDGF),
and fibroblast growth factor (FGF)-2.110 However, while
totipotent ES cells have been used for transplants there
are no consistent data on the use of ES-derived lineage
restricted neural cells. To partially overcome such lim-
itation, protocols have recently been developed to gen-
erate in vitro high numbers of cell type-specific neural
precursors (e.g. oligodendroglial lineage cells, dopa-
minergic neurons) from ES cells.111
Adult NSC
NSC can be isolated from adult human brains and
can be expanded and maintained safely in a chemical-
ly defined medium for years thus supporting the con-
cept that these cells might represent a renewable
source of uncommitted NSC which could be used for
transplantation procedures. These cells show: (i)
growth factor (GF)-dependent proliferation and a sta-
ble growth rate; (ii) capacity for self-renewal; (iii) mul-
tipotentiality; (iv) functional plasticity either over seri-
al in vitro passaging or after several freezing-thawing
cycles. Adult NSC plasticity and functional flexibility
can be modulated in vitro by exposure to different
growth factors. LIF, brain-derived neurotrophic factor
(BDNF), ciliary neurotrophic factor (CNTF), neu-
rotrophin (NT)-3, and NT-4 drive NSC to a neuronal
fate (up to 40-60% of cells in culture), whereas bone
morphogenetic proteins (BMPs), CNTF and LIF
increase the number of NSC-derived astrocytes.112
In vivo experiments aimed at repairing injured CNS
by transplanting multipotent NSC have shown that
these cells might survive transplantation procedures
within the host CNS, and can display notable migra-
tory properties from the site of grafting and maintain
their multipotency. While NSC, transplanted either
intraparenchymally or intrathecally into healthy
rodents, show precise pathways of tissue invasion and
neuronal (i.e., dopaminergic) differentiation,113,114 there
are data indicating that this differentiation pattern
changes when NSC are transplanted into rodents suf-
fering from experimental CNS diseases. In experimen-
tal autoimmune, chemical or traumatic CNS demyeli-
nation, NSC – transplanted intraparenchymally,
intracerebroventricularly (i.c.) or intravenously (i.v.) –
show the ability to selectively reach the areas of tissue
damage, to differentiate into axon-ensheathing oligo-
dendrocytes and to promote functional recovery.115
Accordingly, site-specific dopaminergic neuronal dif-
ferentiation has been obtained by intrastriatal trans-
plantation of undifferentiated syngenic or xenogenic
(human) NSC in rats affected by experimental parkin-
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sonism.116 More recently, i.v.-injected human adult
NSC have been efficacious in promoting functional
recovery in rats affected by experimental intracerebral
hemorrhage or transient cerebral ischemia via termi-
nal differentiation, within the host brain, into neurons
(10%) and astrocytes (75%).117,118 Notably, NSC trans-
plants – both in healthy and diseased rodents –did not
induce tumor formation in immunodeficient mice,
thus strongly suggesting that the in vivo tumorigenic
potential of such a potent cell source is minimal.
BM-derived SC
BM-SC have been recently shown to be able to dif-
ferentiate into neural cells when transplanted into
rodents or humans.119,120 The most challenging example
of the contribution of these cells to the cytoarchitec-
ture of the brain comes from a recent report showing
Y-chromosomes in cerebellar Purkinje neurons of
women who had received BM transplants from male
donors.121 Along with this evidence of BM-SC plastici-
ty, there are other reports that collectively suggest that
these cells could contribute to generating new neurons
in the adult brain by means of (i) transdifferentiation
(direct conversion of transplanted cells into neu-
rons)119,120 and/or (ii) cell fusion (assimilation of trans-
planted cells or their progeny into existing neurons
and formation of heterokaryons).122 The demonstra-
tion that BM-SC and NSC are developmentally plastic
- although this is still a matter of debate123,124 - has
encouraged many attempts aimed at using BM-SC for
brain repair. Animal models of focal demyelination,
ischemic stroke, amyotrophic lateral sclerosis, and
spinal cord injury have been treated with BMSC.125-127
These studies showed that differentiation of BM-SC
into brain cells can be obtained also in experimental
models of brain disorders. However, only a few of
these studies consistently showed that BM-SC differ-
entiated into brain cells may induce functional repair
of the brain. In rats with a demyelinated lesion of the
spinal cord, BM-SC from GFP-expressing mice
(immunoreactive for collagen type I, fibronectin, and
CD44) produced remyelination and improvement of
axonal conduction velocity when transplanted i.v. or
by direct microinjection into the demyelinated spinal
cord of immunosuppressed rats.126 Donor BM-SC
obtained from transgenic mice constitutively express-
ing β-galactosidase (transcriptionally regulated by an
endothelial-specific promoter Tie2) were found, by
perfusion-weighted magnetic resonance imaging
(MRI), in sites of neovascularization where cerebral
blood flow (CBF) was increased.127 The clinical use of
BM-SC in other experimental CNS disorders, such as
amyotrophic lateral sclerosis and spinal cord injury, is
too preliminary to draw any meaningful conclusion
on the reparative potential of these cells.128
The route of cell administration
The route of cell administration is another key issue
in NSC transplantation procedures for CNS diseases.
On the one hand, the anatomo-pathological features
of focal CNS disorders, such as Parkinson’s disease or
SCI, would suggest that direct intralesional cell trans-
plantation might facilitate tissue regeneration of
dopaminergic neurons of the substantia nigra or of
naked axons within a specific segment of the spinal
cord, respectively. On the other hand, the mutifocali-
ty of certain CNS disorders such as amyotrophic later-
al sclerosis, MS, or Alzheimer’s disease, limits per se
NSC-based therapies. However, some recent experi-
ments have shown that, at least, in multifocal inflam-
matory brain disorders these limitations can be over-
come by injecting therapeutic stem cells (e.g. BMSC,
MSC, NSC) into the blood stream or into the cere-
brospinal fluid compartment. Specific homing can be
explained, at least in part, by the constitutive expres-
sion by NSC of a wide array of inflammatory mole-
cules such as adhesion molecules (integrins, selectins,
immunoglobulins, etc.), chemokines, cytokines and
chemokine receptors.129
Differentiation and persistence of NSC in the
targeted tissue 
Although very little is known about the mecha-
nisms instructing the terminal differentiation of NSC
in vivo, there is strong evidence that the local environ-
ment might dictate the fate of transplanted uncommit-
ted NSC. In this respect, undifferentiated multipotent
NSC or even totipotent ES cells, transplanted in differ-
ent experimental neurological conditions, have shown
considerable capacity to restrict their fate in response
to tissue-specific cues and to replace non-functioning
neural cells of different lineages. Totipotent ES cells
display a preferential terminal differentiation into
either myelinating oligodendrocytes or TH+ neurons
when transplanted into rodents affected by experi-
mental acute SCI or 6-OH-DA-induced parkinsonism,
respectively.130 Even more efficiently, multipotent
growth factor-responsive NSC show neuronal- or
glial-restricted fate when transplanted in animal mod-
els of neuronal (e.g. Parkinson’s disease, stroke) or
myelin dysfunction (e.g. EAE, SCI),113,115,131-133 respective-
ly. Thus, the local environment may dictate the fate of
transplanted NSC. However, transplanted NSC might
exert their therapeutic effect not only by differentiat-
ing into lineage-restricted daughter cells and by func-
tionally integrating into the host tissue. It has recently
been shown that upon transplantation – independent-
ly of the characteristics of the injured area of CNS into
which the NSC have been transplanted – NSC might
remain in an undifferentiated state (e.g. lack differen-
tiation antigens, round-shaped morphology, perivas-
cular localization) but continue to release neurotroph-
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ic growth factors (FGF-2, BDNF, GDNF, etc.).115 This
evidence suggests that NSC might repair brain dam-
age also by remaining in their undifferentiated state
and acting as bystander regulators of neuronal and/or
oligodendrocytic rescue via the constitutive or
induced release of neurotrophic molecules.
Epithelial SC and regenerative medicine
Epidermal and limbal SC
Human epidermis consists of a stratified squamous
epithelium composed of keratinocytes organized in
distinct cellular layers. Basal keratinocytes that
become committed to terminal differentiation stop
dividing, migrate upwards and initiate the process of
keratinization. This leads to the sequential formation
of the stratum spinosum, stratum granulosum and
stratum corneum, the last being composed of anucle-
ate corneocytes continuously shed into the environ-
ment. For each corneocyte shed from the epidermal
surface, a basal keratinocyte must undergo a round of
cell division to replace it.
The surface of the human eye is covered with high-
ly specialized conjunctival and limbal-corneal epithe-
lia, which are formed by two genotypically different
keratinocytes.134 The corneal epithelium is a transpar-
ent, flat, stratified squamous epithelium with a cuboid
basal layer lying on the avascular corneal stroma by
Bowman’s layer. The narrow transitional zone
between the cornea and the bulbar conjunctiva is
referred to as the limbus. The limbal epithelium con-
sists of several layers of keratinocytes organized into
well developed rete ridges, devoid of goblet cells and
populated by Langerhans’ cells and melanocytes.
Epidermal epithelium is replaced approximately
monthly whereas corneal epithelium is replaced about
every year. To accomplish their self-renewal process,
these epithelia rely on the presence of stem and tran-
sient amplifying (TA) cells, the latter defined as non-
stem daughters of SC that are able to divide only a
few times before the onset of terminal differentia-
tion.135-136 Separate populations of SC have been sug-
gested to exist in interfollicular epidermis, hair follicles
and sebaceous glands, at least under steady-state con-
ditions.136-142 However, the bulge-containing region of
the hair follicle is thought to represent the main reser-
voir of skin keratinocyte SC.136,140 Human corneal SC
are located exclusively in the basal layer of the limbal
epithelium.138,141 Primary cultures of human ker-
atinocytes can be used to identify and characterize
epithelial SC. Three types of keratinocytes with dif-
ferent proliferative capacities have been identified in
human epidermis, hair follicles, limbal and conjuncti-
val epithelia, and are referred to as holoclones, mero-
clones and paraclones.137,138,142,143
The holoclone, considered the keratinocyte SC.137
The holoclone is identical to the multipotent SC locat-
ed in the bulge of the hair follicle, is located in the lim-
bal but not in the corneal epithelium, generates a
mature epithelium in vivo, has telomerase activity, long
telomeres and an astonishing proliferative poten-
tial,137,138,142,143 which are all hallmarks of SC. A single
holoclone can produce as many as 1045 keratinocytes
before senescence, which occurs after more than 180
cell divisions in culture and dozens of cell passages. A
human being contains 8×1010 epidermal keratinocytes
scattered on approximately 2 m2 of body surface.
Thus, a single holoclone can generate enough epithe-
lial cells to cover 1.25×1034 human beings or an area
equivalent to 2.1×1028 Km2.
The paraclone is a TA cell, which is committed to a
maximum of 15 cell divisions and generates aborted
colonies containing only terminally differentiated
cells.137,138 The meroclone is an intermediate type of cell
and is probably a reservoir of TA cells. 
Cultured epithelial SC and regenerative medicine
Keratinocyte SC are currently used to permanently
restore many severely damaged epithelial surfaces,
such as epidermis, cornea and mucosal membranes.144–149
Human epidermal keratinocytes propagated in vitro
generate sheets of stratified epithelium which main-
tains the characteristics of authentic epidermis, includ-
ing functional melanocytes physiologically organized
in the basal layer. Autologous cultured keratinocytes
have been used worldwide to regenerate the epider-
mis in thousands of burn victims.144,150 Human epider-
mis is renewed monthly. Permanent epidermal regen-
eration – over 20 years of follow-up and hence over
200 renewing cycles – has been achieved in these
patients. Thus, this technology has been proven to be
life-saving. A mature epidermis regenerates within a
week after grafting.144,145 Hemidesmosomes and basal
lamina reform conjointly and regenerate a functional
dermal-epidermal junction within the first month
after transplantation, although full maturation of
anchoring fibrils requires approximately one year. A
mild hyperkeratosis is usually present at 4-8 months
after grafting and disappears afterwards. The dermal-
epidermal junction is usually flattened during the ini-
tial semester. Shallow but defined rete ridges appear
after 8-12 months and their depth progressively
increases. The regenerated epidermis contains a nor-
mal population of Langerhans’ cells and melanocytes,
the latter forming an epidermal melanin unit already
at 4 months after grafting. Normal histologic features
are maintained for years after transplantation.
Pathologic, dysplastic or pre-malignant changes are
not observed.
Epidermal grafts for burn victims are usually pre-
pared from full-thickness skin biopsies taken from
hairy body sites in order to maximize the number of
SC used for graft preparation. Therefore, in most
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patients, it is not possible to establish whether regen-
erated epidermis originated from interfollicular or hair
follicle SC.
Ocular chemical burns are characterized by a deple-
tion of limbal cells thereby leading to corneal re-epithe-
lialization by bulbar conjunctival cells.151 This abnormal
wound healing process induces neo-vascularization,
chronic inflammation and stromal scarring. Total limbal
SC deficiency eventually leads to corneal opacification
and visual loss. Allogeneic corneal grafts, aimed at
replacing the corneal stroma, are not successful in these
patients, unless the limbal SC population has been
restored by limbal grafts taken from the uninjured eye.152
It has been shown that cultures of autologous limbal SC,
isolated from a tiny (1-2 mm2) limbal biopsy taken from
the uninjured eye, permanently (over 5 years follow-up
to date) restore corneal integrity and function, that is
normal visual acuity, in patients with unilateral limbal
stem cell deficiency unresponsive to conventional surgi-
cal therapy, such as penetrating or lamellar keratoplas-
ty.146,148 The corneal epithelium and visual acuity can also
be restored in blind patients presenting with bilateral
limbal SC deficiency unresponsive to multiple kerato-
plasty.152,153 These patients can be treated with allogeneic
cultured limbal cells. The persistence of donor cells has
been formally proven at the last available (3 years) fol-
low-up.
However, restoration of bilateral SC deficiency by
means of cultured allogeneic limbal SC requires immu-
nosuppressive therapy. Further studies are required to
investigate whether SC isolated from other stratified
epithelia have enough plasticity to generate an authen-
tic corneal epithelium. Indeed, if autologous epidermal
or oral mucosa SC could be reprogrammed to produce
limbal SC, corneal epithelium could be regenerated in
patients with bilateral limbal SC deficiency without the
need for immunosuppression. Urethral epithelium has
been generated by cultured urethral SC in patients with
posterior hypospadias, which is characterized by the
congenital absence of urethral epithelium in the entire
penis.149 Palate-derived epithelial cells have been used to
regenerate palate epithelium and gingival mucosa.154
The sum of clinical data accumulated during the last
2 decades proves that cultured epithelial SC can regen-
erate a functional tissue when transplanted back into
patients. Collectively, the permanent epidermal regen-
eration achieved in burned patients by means of ker-
atinocytes cultivated from glabrous skin, the mainte-
nance of palm/sole-specific histological and biochemi-
cal features in the regenerated epidermis and corneal
regeneration by means of allogeneic cultured limbal
cells provide compelling evidence that (i) keratinocyte
SC are maintained in culture, even if they are released
from the in vivo control mechanism designed to keep
them in a slow-cycling state; (ii) cultured keratinocyte
SC take and regenerate a renewing epithelium in vivo;
(iii) keratinocytes endowed with authentic SC proper-
ties are also located in the interfollicular epidermis.
These data add strength to the notion that the bulge-
containing region of the hair follicle is likely to repre-
sent the main reservoir but not the only residence of
keratinocyte SC, and that bulge-derived SC are likely to
play a role in regenerating epidermis only in emergency
situations.136 For instance, it is common knowledge that
partial-thickness burns, which are characterized by
total epidermal destruction but preservation of skin
appendages, can be healed by keratinocytes migrating
from hair follicles. It is also likely that SC migrating
from the bulge can restore the population of SC nor-
mally present in the epidermal basal layer.
Cartilage and bone repair
Mesenchymal stem/progenitor cells
Friedenstein et al. were the first to identify a cell
population with a strong osteogenic potential in a sin-
gle cell suspension from adult BM.155
Osteogenic cells were similarly derived from the
thymus and the spleen of guinea pigs and rabbits.
Following this pioneering work, many research
groups have more recently isolated mesenchymal
stem/progenitor cells from adult tissues. These cells
are able to undergo differentiation pathways other
than those they were initially determined to follow.
Several groups have isolated pluripotent stem/progen-
itor cells from the BM stroma. BM stroma is com-
posed of a heterogeneous variety of cell types among
which BM stromal cells are the essential elements of
the hematopoietic microenvironment, via direct cell-
cell contact and by supplying soluble mediators.156
Recent studies demonstrated the pluripotency of
BM stromal cells showing that they can differentiate
into ectodermal and endodermal cells such as astro-
cytes, oligodendrocytes, neurons, hepatocytes (see
above and Table 4). Nevertheless, it is questionable that
BM stromal cells are indeed a homogeneous popula-
tion of adult SC. On the contrary, several pieces of evi-
dence indicate that BM-SC are a very heterogeneous
population comprising cells at different stages of com-
mitment and that cells with stem/early progenitor
characteristics, if present, are only a subpopulation of
the whole cell population. Plated at low density, BM
stromal cells form distinct and heterogeneous colonies
derived from a single cell (colony-forming units-fibrob-
lastic: CFU-F). Colonies are different in shape and size,
reflecting differences in the proliferation and growth
rate of the CFU-F. After some time in culture, pheno-
typic differences are more evident. Some CFU-F are tri-
potential in that they differentiate in vitro into
osteoblasts, chondrocytes and adipocytes, others are
bi-potential, differentiating only towards a chondro-
osteogenic phenotype, and a third group includes only
osteogenic clones.156 During culture, tri-potential clones
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first lose adipogenic differentiation, then chondrogenic
and lastly osteogenic potential. The heterogeneity of
the BM stromal cell clones is also observed in vivo, since
only 60% of clones are osteogenic.158 As discussed
above, Jiang et al.17 have also isolated from the BM a
cell population, MAPC, with true SC properties.
Pluripotent cells, with properties similar to those from
BM, have also been isolated from human adipose tis-
sue.159 Capillary pericytes are probably an additional
source of cells with stem/progenitor properties. It has
been suggested that marrow pericytes and marrow
stromal cells are the same cell population.160 The peri-
cyte is a cell of mesenchymal origin with long cellular
processes surrounding capillaries. Pericytes have been
isolated from capillaries of different tissues, including
cerebral cortex, peripheral nerves, retina, skeletal mus-
cle and the lungs. When implanted in diffusion cham-
bers in vivo, some of these pericytes spontaneously
form bone and cartilage.161 Vascular smooth muscle
cells produce bone-specific matrix proteins such as
osteopontin, osteonectin, and matrix gla protein.162
Osteoprogenitors have been isolated from peripheral
blood, although the efficiency of these progenitors is
very low, 163 and from the skeletal muscle.164
Engineering cartilage and bone 
Implanting stem/progenitor cells in a suitable scaffold versus
implanting of a preformed tissue
Taking advantage of cells with chondro-osteogenic
potential, two main approaches have been proposed
for the repair of traumatic lesions of cartilage and bone:
(i) implanting undifferentiated pluripotent cells in a car-
rier scaffold and (ii) implanting a tissue preformed in
vitro.The first approach relies on the fact that pluripo-
tent cells are activated toward a specific differentiation
pathway in the appropriate environment. According to
the second strategy, undifferentiated pluripotent cells
are associated with a suitable scaffold and cultured in
vitro within a bioreactor under conditions favoring the
formation of transplantable tissue. In both cases the
choice of the optimal cell type and the choice of the
most suitable scaffold are critical for the success of the
therapy.
Dedifferentiated chondrocytes
Human articular chondrocytes derived from articular
cartilage biopsies and grown as a monolayer dediffer-
entiate with culture passages and lose their chondro-
genic phenotype. It has been suggested that dedifferen-
tiated chondrocytes are cells that have regressed to a
more primitive stage thus being able to redirect their
differentiation towards a different phenotype and
therefore, having the same properties as pluripotent
MSC. Nevertheless, cultured dedifferentiated chondro-
cytes have only a limited proliferative potential. The
number of cell divisions they can undergo decreases
with the increase of the donor’s age.165 In addition,
within a few culture passages, dedifferentiated chon-
drocytes lose their ability to redifferentiate upon in vitro
transfer into a 3-dimensional environment166 and upon
subcutaneous implantation into an immunodeficient
mouse. The presence of growth factors, such as basic
fibroblast growth factor (FGF-2) and transforming
growth factor β1 (TGFβ1) in the culture increases their
proliferation rate and maintains their redifferentiation
potential longer. Human articular chondrocytes grow
well in medium supplemented with serum, but in
order to be able to redifferentiate both in vitro and in
vivo they need to be rescued by strong chondrogenic
inducers (TGFβ1). In contrast, chondrogenic commit-
ment is maintained when chondrocytes are cultured in
a defined medium supplement, in which serum is sub-
stituted by specific growth factors (in particular FGF-2). 
Mesenchymal stem/progenitor cells
Cells with chondro-osteogenic potential have been
isolated from several tissues, including periosteum,
BM, spleen, thymus, skeletal muscle, adipose tissue,
skin and retina.17,65,159,161,164 However, for several reasons
(limited or hardly accessible tissue source, low fre-
quency of stem/progenitor cells in the cell population,
limited information on the specific cell system, etc.),
BM remains, at the moment, the most widely used cell
system in preclinical and clinical studies on both bone
and cartilage regeneration and repair. The collection of
a limited amount of BM cells is an easy and relatively
safe procedure. BM stromal cells can be expanded in
culture, making it possible to engineer transplantable
constructs made by these cells associated with appro-
priate scaffolds. 
BM stromal cells are responsible for the mainte-
nance of bone turnover throughout life and can be
regarded as mesenchymal progenitor/precursor cells
derived from adult stem cells. Cultured BM stromal
cells can be stimulated to differentiate into cells of tis-
sues of mesodermal origin such as bone, cartilage,
muscle, marrow stroma, tendon, fat and a variety of
other connective tissues167 and, under certain condi-
tions, also into cell types derived from ectoderm and
endoderm (see above). When implanted into immun-
odeficient mice, BM stromal cells combined with min-
eralized three-dimensional scaffolds form a highly
vascularized primary bone tissue.
In vitro culture: a critical step for mesenchymal
stem/progenitor cells
The use of BM stromal cells for the reconstruction of
bone segmental defects requires extensive in vitro
expansion of the cell population maintaining a high
regenerative potential. The properties of BM stromal
cells are profoundly influenced by the microenviron-
mental conditions, including culture conditions. Upon
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Figure 2. Hypotetical models of adult tissue regeneration and stem cell developmental plasticity.
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in vitro expansion, the bone-forming efficiency of in vivo
transplanted BM stromal cells is significantly reduced.157
Culture conditions that allow BM stromal cell expan-
sion without loss of differentiation potential are diffi-
cult to establish. Requirements for in vitro expansion of
BM stromal cells have been investigated.168-172
The CFU-F derived from BM cells undergo clonal
osteogenic, chondrogenic and adipogenic differentia-
tion. When clones were isolated and expanded in the
presence of FGF2, the frequency of clones able to differ-
entiate into the osteogenic, chondrogenic and adi-
pogenic lineages (tripotential clones) increased. This
effect was associated with the cultured cells having
longer telomeres. The observed increase in telomere
length is due to the selection of a subset of progenitor
cells. In the best culture conditions, these cells have an
extended life-span of about 70 doublings and they
retain their differentiation potential for over 50 dou-
blings. 
Culturing BM-SC in the presence of FGF2 is a criti-
cal step for osteogenic development also in vivo. At 4
weeks, bone was observed only in implants loaded
with FGF2-expanded BMSC; at 8 weeks bone was
more than 12% of the total tissue formed in the case
of implants loaded with cells expanded in the pres-
ence of FGF2 while in the control implants, loaded
with cells expanded in the absence of FGF2, bone for-
mation accounted for only 0.5% of the tissue.172
The above data support the concept that BM-SC are
not a homogeneous population of MSC. On the con-
trary, they are a heterogeneous population of mes-
enchymal progenitor/precursor cells. Adding FGF2 to
the culture, maintains cells in a more immature state
and allows the in vitro expansion of osteo-progenitors,
possibly by selecting a specific cell subset. FGF2 is not
sufficient by itself to prevent progressive cell senes-
cence but significatintly increases the frequency of
multipotential clones and allows a large number of
cells, with preserved differentiation potential, to be
obtained for mesenchymal tissue repair.
Choice of suitable scaffolds
Several scaffolds have been developed and used for
tissue engineering. The ideal scaffold is non-immuno-
genic, non-toxic, biocompatible, biodegradable and
easy to manufacture. Scaffolds should permit easy dif-
fusion of nutrients and cellular waste products. At the
same time, they should provide initial good mechani-
cal support for cells and extracellular matrix during the
repair process. The degradation rate of the scaffold
should be tuned to the rate of production of extracel-
lular matrix by the cells.
Scaffolds currently used for cartilage repair are made
of both naturally occurring polymers and synthetic
polymers. Collagen (in most cases type I collagen
derived from porcine and bovine skin), fibrin, (current-
ly used in the clinic as fibrin glue), and hyaluronic acid
(often after partial esterification) are the most fre-
quently used natural polymers. Examples of synthetic
polymers are polylactic acid and polyglycolic acid
(homo- or heteropolymers), and polycaprolactone. All
these polymers can be shaped into membrane films,
threads, sponges and hydrogels.
Porous bioceramics made of hydroxy-apatite (HA),
tri-calcium phosphate (TCP) or a mixture of the two
are the most widely used scaffolds for bone repair. A
relatively higher concentration of TCP in the bioce-
ramic usually results in higher resorbability. These
ceramic scaffolds have osteoconducive properties and
can integrate with the patient’s bone tissue.
Alternative mineralized scaffolds are derived from
cadaveric or animal bones, and from coral exoskele-
ton. Bioreactors could improve the production of
transplantable engineered tissues and in particular of
engineered cartilage by providing an efficient and spa-
tially uniform cell seeding in three-dimensional scaf-
folds and by allowing better nutrient diffusion.
Furthermore, bioreactors can expose forming engi-
neered cartilage to specific physical stimuli. 
Preclinical and clinical studies
Cartilage repair
Autologous chondrocyte implantation (ACI)
Chondrocytes are isolated from a biopsy of healthy
articular cartilage from a low weight-bearing area of
joint and expanded in monolayer culture. Chon-
drocytes are reinjected under an autologous periosteal
flap, sutured and/or glued onto the cartilage defect173
and good to excellent results are obtained in more
than 90% of cartilage lesions.174
Limitations of the classical ACI procedure are relat-
ed to chondrocyte culture conditions and graft fixation
methods, especially for osteochondral defects. As pos-
sibe solutions to overcome some of these problems,
cell delivery systems based on collagen membranes or
three-dimensional hyaluronic acid scaffolds have been
proposed.175
Engineering cartilage
The use of in vitro engineered cartilage for treatment
of cartilage lesions is still at a preclinical stage. To test
the chondrogenic potential of human cells and their
interactions with natural and synthetic scaffolds, con-
structs can be implanted subcutaneously into immun-
odeficient mice. Nevertheless, in this animal model,
the results can be significantly biased by the absence of
biomechanical forces acting on the forming cartilage. 
Several experiments have been performed in rabbit
models to test the efficacy of different scaffolds, but
graft survival and engineered cartilage remodeling
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under loading are under investigation in weight-bear-
ing large animal models (e.g., sheeps, goats, dogs, and
horses). 
Repair of large bone defects
Systemic injection of osteogenic cells
Conflicting data concerning BM stromal cell engraft-
ment after systemic injection have been reported in
the literature. Following intravenous infusion, SC are
capable of homing not only to the BM of immunode-
ficient176 or irradiated mice177 and irradiated baboons,178
but also to multiple sites, such as bone, cartilage, lungs
and spleen. 
In humans, allogeneic BM transplantation has been
used to treat 3 children with severe osteogenesis
imperfecta.179,180 Three months after transplantation,
total body bone mineral content was increased and
new dense bone formation was observed in trabecular
bone. The clinical conditions were, perhaps, improved
by engraftment of functional mesenchymal progenitor
cells. BM stromal cell engraftment has been clearly
shown in sheep fetuses. Co-transplantation of human
stromal cells improved the long-term engraftment of
HSC, whereas stromal cells transplanted alone
remained functional in the hematopoietic microenvi-
ronment181 and persisted in multiple tissues undergo-
ing site-specific differentiation for more than 1 year
after the transplant.182
Engineering bone
Based on the encouraging results obtained with
rodents and large animal models, clinical trials were
initiated in humans with large (4 to 7 cm) bone
defects, in whom traditional therapeutic approaches
had proven unsuccessful.183 Whole BM was harvested
from each patient, ex vivo expanded BM stromal cells
were loaded on a macroporous hydroxyapatite scaf-
fold of the shape and size of the missing bone seg-
ment and the scaffold implanted into the bone defect.
External fixation was provided for initial stability. All
patients recovered limb function by between 6 and 12
months. The expected recovery time after a tradition-
al approach would have been much longer, under the
most favorable conditions and in the absence of com-
plications.
Results so far obtained in cartilage and bone tissue
engineering are very encouraging, but still not opti-
mal. Additional experimental and clinical work is
needed before this therapeutic approach can be rou-
tinely used in clinical practice. Questions requiring
answers and problems awaiting solutions regard the
optimal origin of cells, the availability of well-defined
serum-free media for SC culture, the possibility of
using allogeneic cells and the development of a new
generation of reabsorbable scaffolds and more
advanced bioreactors.
Conclusions and perspectives
Adult, tissue-specific SC have proven to be a power-
ful therapeutic tool for regenerative medicine. In par-
ticular, BM and circulating HSC are routinely used to
restore altered hematopoiesis. However, although the
proof of principle that BM-SC contribute to non-
hematopoietic tissues has been provided, numerous
studies have shown that the phenomenon of SC devel-
opmental plasticity is rare and its frequency may not
be, at present, therapeutically relevant. The recruit-
ment of BM-SC to other tissues seems to be injury-
dependent and the key regulators of transdifferentiation
are still unknown. Taken together, the data reviewed
here indicate that the physiological relevance of SC
plasticity may be negligible. However, it is possible
that adult SC could eventually be used for clinical pro-
grams of regenerative medicine. To achieve this goal,
basic scientists need to better characterize the cell pop-
ulation responsible for the generation of mature cells of
different tissues [SC (?) Mature precursors (?)]. We also
need a better understanding of the molecular mecha-
nisms regulating the balance between SC self-renew-
al/differentiation and how to induce more efficient
production of mature tissue cells. Identification of the
tissue-specific and injury-related signals that regulate
homing, engraftment and expansion of BM-SC at the
site of tissue damage as well as an understanding of the
mechanisms inducing fusion or plasticity should also
help to increase the therapeutic potential of adult SC
(Figure 2). Moreover, recent data indicate that, along
with tissue-specific SC, there may be a rare  pluripo-
tent SC population, which circulates in the PB at low
frequency and can be recruited at the site of tissue
damage for tissue repair (Figure 3). 
Of note, the controversy between cell fusion vs trans-
differentiation has been further fuelled by very recent
data showing differentiation of HSC into liver cells59
and NSC into endothelial cells,124 in vitro, without cell
fusion. However, cell fusion may be considered a
mechanism of cell plasticity, although not necessarily
involving SC.184,185 In addition, from a therapeutic point
of view, as long as the function of the damaged tissue
is restored it may not be crucial that true transdiffer-
entiation occurs, as demonstrated in the FAH model of
liver injury. Additional strategies to improve the ther-
apeutic potential may be ex vivo culture of BM-SC to
induce their initial commitment to customized tissue
cells, genetic manipulation of stem/progenitor cells to
induce their proliferative advantage over resident cells,
increasing the number of SC available for tissue repair
by the use of hematopoietic cytokines (e.g. G-CSF,
SCF) to mobilize HSC or the post-transplant use of
cytokines such as HGF in the case of liver tissue dam-
age. Finally, the very concept of SC as a definite entity
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is under discussion.186 Data discussed in this review
indicate that the function of SC can  sometimes be
acquired by more mature progenitor/precursor cells
under appropriate microenvironmental stimuli.
This finding supports the view that cycling progen-
itors, as opposed to quiescent SC, may activate differ-
ent genetic programs leading to transdifferentiation
(Figure 1).
Although these issues need to be properly
addressed, several clinical trials have already been
completed and many more are underway to test the
concept of adult SC developmental plasticity.
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